J
Jyoti D. Patel
Researcher at Northwestern University
Publications - 219
Citations - 11242
Jyoti D. Patel is an academic researcher from Northwestern University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 44, co-authored 180 publications receiving 9101 citations. Previous affiliations of Jyoti D. Patel include University of Illinois at Chicago & University of Chicago.
Papers
More filters
Journal ArticleDOI
Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
Vincent A. Miller,Mark G. Kris,Neelain Shah,Jyoti D. Patel,Christopher G. Azzoli,Jorge Gomez,Lee M. Krug,William Pao,Naiyer A. Rizvi,Barbara Pizzo,Leslie B. Tyson,Ennapadam Venkatraman,Leah Ben-Porat,Natalie Memoli,Manreen Zakowski,Valerie W. Rusch,Robert T. Heelan +16 more
TL;DR: The data suggest that individuals in whom gefitinib is efficacious are more likely to have adenocarcinomas of the bronchioloalveolar subtype and to be never smokers, and suggest that NSCLC has a different biology in patients who never smoked and those with bronchiola alveolar carcinoma.
Journal ArticleDOI
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Jyoti D. Patel,Lada Krilov,Sylvia Adams,Carol Aghajanian,Ethan Basch,Marcia S. Brose,William L. Carroll,Marcos de Lima,Mark R. Gilbert,Mark G. Kris,John L. Marshall,Gregory A. Masters,Steven J. O'Day,Blase N. Polite,Gary K. Schwartz,Sunil Sharma,Ian M. Thompson,Nicholas J. Vogelzang,Bruce J. Roth +18 more
TL;DR: Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology represents the invaluable contributions of thousands of patients who participate in clinical trials and the scientists who conduct basic and clinical research.
Journal ArticleDOI
Non–Small Cell Lung Cancer
David S. Ettinger,Wallace Akerley,Gerold Bepler,Andrew C. Chang,Richard T. Cheney,Lucian R. Chirieac,Thomas A. D'Amico,Todd L. Demmy,Steven J. Feigenberg,Robert A. Figlin,Ramaswamy Govindan,Frederic W. Grannis,Thierry Jahan,Mohammad Jahanzeb,Anne Kessinger,Ritsuko Komaki,Mark G. Kris,Corey J. Langer,Quynh-Thu Le,Renato G. Martins,Gregory A. Otterson,Jyoti D. Patel,Francisco Robert,David J. Sugarbaker,Douglas E. Wood +24 more
TL;DR: In 2010, approximately 222,520 new cases of lung or bronchial cancer will be diagnosed in the USA, and 157,300 patients are expected to die of this disease as discussed by the authors.
Journal ArticleDOI
Non-small cell lung cancer: Clinical practice guidelines in oncology
David S. Ettinger,Wallace Akerley,Gerold Bepler,Matthew G. Blum,Andrew C. Chang,Richard T. Cheney,Lucian R. Chirieac,Thomas A. D'Amico,Todd L. Demmy,Apar Kishor Ganti,Ramaswamy Govindan,Frederic W. Grannis,Thierry Jahan,Mohammad Jahanzeb,David H. Johnson,Anne Kessinger,Ritsuko Komaki,Feng Ming Kong,Mark G. Kris,Lee M. Krug,Quynh-Thu Le,Inga T. Lennes,Renato Martins,Janis P. O'Malley,Raymond U. Osarogiagbon,Gregory A. Otterson,Jyoti D. Patel,Katherine M.W. Pisters,Karen L. Reckamp,Gregory J. Riely,Eric M. Rohren,George R. Simon,Scott J. Swanson,Douglas E. Wood,Stephen C. Yang +34 more
TL;DR: The NCCN Clinical Practice Guidelines in Oncology for Small Cell Lung Cancer (SCLC) focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease as discussed by the authors.
Journal ArticleDOI
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong,Steven G. DuBois,Shivaani Kummar,Anna F. Farago,Catherine M. Albert,Kristoffer Staal Rohrberg,Cornelis M. van Tilburg,Cornelis M. van Tilburg,Ramamoorthy Nagasubramanian,Jordan Berlin,Noah Federman,Leo Mascarenhas,Birgit Geoerger,Afshin Dowlati,Alberto S. Pappo,Stefan S. Bielack,François Doz,Ray McDermott,Jyoti D. Patel,Russell J. Schilder,Makoto Tahara,Stefan M. Pfister,Stefan M. Pfister,Olaf Witt,Olaf Witt,Marc Ladanyi,Erin R. Rudzinski,Shivani Nanda,Barrett H. Childs,Theodore W. Laetsch,David M. Hyman,David M. Hyman,Alexander Drilon,Alexander Drilon +33 more
TL;DR: These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active and indicate that long-term administration of larot rectinib are feasible.